It is important to talk to your healthcare team about what side-effects you may be experiencing.
You are able to learn more about side effects from the patient information leaflet which comes with your mediation or via the Yellow Card Scheme.
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
Presentations from the PrEP summit now online
US green light for Gilead’s HIV combo
NHS England sets out plans to be first in the world to eliminate Hepatitis C.
Fast-Track London Will Only Work If We Keep Our Foot On The Accelerator
Have your say: contribute to the UN’s work to end TB, HIV and viral hepatitis in the WHO European Region.
The National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for AbbVie’s MAVIRET
Blood samples from the 1950s help rewrite the history of hepatitis C.
Research on HIV cure: Mapping the ethics landscape.
Just because a partner has undetectable viral load, it doesn’t rule out the need for PrEP or PEP
David Rowlands provides an in depth look at his treatment and care experience as well as breaking down the barriers placed on the disease due to stigma and challenging your perceptions on hepatitis C.